BIOMARKER-GUIDED EARLY CLARITHROMYCIN TREATMENT TO PREVENT SEPSIS PROGRESSION IN COMMUNITY-ACQUIRED PNEUMONIA: THE REACT RANDOMIZED CLINICAL TRIAL